References
- Chee WJY, Chew SY, Than LTL. Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health. Microb Cell Fact Internet]. 2020;19. cited 2022 Mar 2. Available from https://pubmed.ncbi.nlm.nih.gov/33160356/
- Amabebe E, Anumba DOC. The vaginal microenvironment: the physiologic role of lactobacilli. Front Med. 2018;5:181.
- Rosca AS, Castro J, Sousa LG, et al. Gardnerella and vaginal health: the truth is out there. FEMS Microbiol Rev. 2020;44:73–105.
- Abou Chacra L, Fenollar F, Diop K. Bacterial vaginosis: what do we currently know? Front Cell Infect Microbiol. 2022;11:1393.
- Reiter S, Spadt SK. Bacterial vaginosis: a primer for clinicians. Postgrad Med. 2019;131:8–18.
- Fettweis JM, Serrano MG, Girerd PH, et al. A new era of the vaginal microbiome: advances using next-generation sequencing. Chem Biodivers Internet]. 2012;95:965–976. cited 2022 Mar 3. Available from https://pubmed.ncbi.nlm.nih.gov/22589096/
- Onderdonk AB, Delaney ML, Fichorova RN. The Human Microbiome during Bacterial Vaginosis. Clin Microbiol Rev. Internet]. 2016;29(2):223–238. cited 2019 Feb 14. Available from http://cmr.asm.org/lookup/doi/10.1128/CMR.00075-15
- Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol Internet]. 2005;106:1013–1023. cited 2019 Feb 12. Available from http://www.ncbi.nlm.nih.gov/pubmed/16260520
- Muzny CA, Taylor CM, Swords WE, et al. An updated conceptual model on the pathogenesis of bacterial vaginosis. J Infect Dis. 2019;220(9):1399–1405.
- Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):1–6.
- Workowski K, Bolan G. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1–137.
- Sobel JD, Sobel R. Current and emerging pharmacotherapy for recurrent bacterial vaginosis. Expert Opin Pharmacother. 2021;22(12):1593–1600.
- Vodstrcil LA, Muzny CA, Plummer EL, et al. Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment. BMC Med Internet]. 2021;191:1–12. cited 2021 Nov 17. Available from https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-02077-3
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines. MMWR Recomm Rep. 2021;70:1–187.
- Redelinghuys MJ, Geldenhuys J, Jung H, et al. Bacterial vaginosis: current diagnostic avenues and future opportunities. Front Cell Infect Microbiol. 2020;10. 10.3389/fcimb.2020.00010
- Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193:1478–1486.
- Gustin AT, Thurman AR, Chandra N, et al. Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis. Am J Obstet Gynecol Internet]. 2022;226:225.e1–225.e15. cited 2022 Mar 8. Available from https://pubmed.ncbi.nlm.nih.gov/34560047/
- Algburi A, Volski A, Chikindas ML. Natural antimicrobials subtilosin and lauramide arginine ethyl ester synergize with conventional antibiotics clindamycin and metronidazole against biofilms of Gardnerella vaginalis but not against biofilms of healthy vaginal lactobacilli. Pathog Dis Internet]. 2015 ;73(5). cited 2022 Mar 8. Available from https://pubmed.ncbi.nlm.nih.gov/25838136/
- Gottschick C, Szafranski SP, Kunze B, et al. Screening of compounds against gardnerella vaginalis biofilms. Fredricks DN, editor. PLoS One. 2016;11:e0154086. cited 2019 Feb 12. Available from https://dx.plos.org/10.1371/journal.pone.0154086
- Bradshaw CS, Sobel JD. Current treatment of bacterial vaginosis—limitations and need for innovation. J Infect Dis Internet]. 2016;214(1):S14–S20. cited 2019 Feb 12. Available from https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jiw159
- Machado D, Castro J, Palmeira-de-oliveira A, et al. Bacterial vaginosis biofilms: challenges to current therapies and emerging solutions. Front Microbiol Internet]. 2016;6. cited 2019 Feb 12. Available from http://journal.frontiersin.org/Article/10.3389/fmicb.2015.01528/abstract
- Surapaneni S, Akins R, Sobel JD. Recurrent bacterial vaginosis: an unmet therapeutic challenge. experience with a combination pharmacotherapy long-term suppressive regimen. Sex Transm Dis Internet]. 2021;48(10):761–765. cited 2022 Apr 23. Available from https://pubmed.ncbi.nlm.nih.gov/34110746/
- Marrazzo JM, Dombrowski JC, Wierzbicki MR, et al. Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial. Clin Infect Dis. 2019;68(5):803–809.
- Rosca A, Castro J, Sousa LGV, et al. In vitro interactions within a biofilm containing three species found in bacterial vaginosis (BV) support the higher antimicrobial tolerance associated with BV recurrence. J Antimicrob Chemother. 2022. in press. DOI:10.1093/jac/dkac155.